Insights into the Structure, Function, and Ligand Discovery of the Large Neutral Amino Acid Transporter 1, LAT1
Представления о структуре, функции и поиске лигандов большого нейтрального аминокислотного транспортера 1 (LAT1)
2018-04-24
SCID: 54.1/errfcejf
Discuss with AI
LAT1 (SLC7A5)LAT1 inhibitorsamino acid transporterblood–brain barrierhomology modeling
Figures from the paper
Abstract (AI)
The large neutral amino acid transporter 1 (LAT1, or SLC7A5) is a sodium- and pH-independent transporter, which supplies essential amino acids (e.g., leucine, phenylalanine) to cells. It plays an important role at the Blood–Brain Barrier (BBB) where it facilitates the transport of thyroid hormones, pharmaceuticals (e.g., l-DOPA, gabapentin), and metabolites into the brain. Moreover, its expression is highly upregulated in various types of human cancer that are characterized by an intense demand for amino acids for growth and proliferation. Therefore, LAT1 is believed to be an important drug target for cancer treatment. With the crystallization of the arginine/agmatine antiporter (AdiC) from Escherichia Coli, numerous homology models of LAT1 have been built to elucidate the substrate binding site, ligand–transporter interaction, and structure–function relationship. The use of these models in combination with molecular docking and experimental testing has identified novel chemotypes of ligands of LAT1. Here, we highlight the structure, function, transport mechanism, and homology modeling of LAT1. Additionally, results from structure–function studies performed on LAT1 are addressed, which have enhanced our knowledge of the mechanism of substrate binding and translocation. This is followed by a discussion on ligand- and structure-based approaches, with an emphasis on elucidating the molecular basis of LAT1 inhibition. Finally, we provide an exhaustive summary of different LAT1 inhibitors that have been identified so far, including the recently discovered irreversible covalent inhibitors.
Key Findings
1
Homology modeling based on the bacterial transporter AdiC, combined with molecular docking and experimental testing, has revealed novel LAT1 ligand chemotypes.
2
LAT1 expression is strongly upregulated in diverse human cancers, reflecting high amino-acid demands and supporting its potential as a cancer-drug target.
3
LAT1 is a sodium- and pH-independent transporter that supplies essential amino acids and transports hormones, pharmaceuticals, and metabolites across the blood–brain barrier.
4
Structure–function studies have advanced understanding of LAT1 substrate binding and translocation mechanisms.
5
The review summarizes structure- and ligand-based strategies for LAT1 inhibition, including recently identified irreversible covalent inhibitors.
Research Object
Large neutral amino acid transporter 1 (LAT1, SLC7A5)
Research Subject
LAT1 structure, transport function and mechanism, substrate binding and translocation, and the molecular basis of ligand interaction and inhibition
Publication Details
Publication Date
2018-04-24
Journal
Publisher
ISSN
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest